Latest Articles

Publication Date
Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies.

Endometriosis is frequently managed with hormonal suppression that can induce hypoestrogenism during a period when many patients are still accruing peak bone mass. This narrative review summarizes current clinical and …

Published: Aug. 19, 2026, midnight
GnRH Analogues for the Treatment of Endometriosis-Related Pain: A Narrative Review.

Endometriosis is a chronic estrogen-dependent condition affecting women of reproductive age and commonly presents with dysmenorrhea, chronic pelvic pain, dyspareunia, and infertility. In a substantial proportion of patients, pain persists …

Published: July 11, 2026, midnight
Effect of Medical Therapies for Endometriosis on Bone Health: A Systematic Review and Meta-analysis.

To evaluate the effect of endometriosis medical therapies on bone mineral density (BMD).

Published: March 19, 2026, midnight
Dydrogesterone and Letrozole Combination for the Treatment of Endometriosis: A Mechanism-Based Therapeutic Approach.

Endometriosis is a complex, estrogen-dependent disease with limited effective treatments that often focus on symptom management rather than addressing the underlying pathology. Current therapies, such as progestins and GnRH agonists, …

Published: Feb. 13, 2026, midnight
Effect of Astragalus sinicus Ethanol Extract on Menopausal Symptoms in an Ovariectomized (OVX) Mouse Model.

As the aging population grows, the proportion of postmenopausal women is also increasing. Menopause can cause various symptoms and reduce quality of life. Hormone replacement therapy (HRT) is a common …

Published: Jan. 23, 2026, midnight
Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist.

Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/pharmacodynamic (PK/PD) model for merigolix, …

Published: Dec. 20, 2025, midnight
Impact of Physical Rehabilitation on Endometriosis and Adenomyosis-Related Symptoms: A Systematic Review and Meta-Analysis.

Objectives: The aim of this study is to summarize recent evidence of the effectiveness of rehabilitation interventions in managing symptoms related to endometriosis and adenomyosis. Methods: The review protocol was …

Published: Nov. 21, 2025, midnight
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss …

Published: Nov. 7, 2025, midnight
Tolerability and Shared Decision-Making in the Hormonal Management of Endometriosis-Associated Pain.

Background: The management of endometriosis-associated pain has traditionally focused on analgesic efficacy. However, with high-level evidence demonstrating therapeutic equivalence among principal hormonal classes, the paradigm has shifted towards a patient-centred …

Published: Sept. 18, 2025, midnight
Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review.

Endometriosis is a chronic gynecological condition commonly associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility. Owing to the limitations and adverse effects of traditional hormonal therapies, this study aimed to …

Published: Sept. 12, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!